DK2782602T3 - Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis - Google Patents

Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis

Info

Publication number
DK2782602T3
DK2782602T3 DK12790904.2T DK12790904T DK2782602T3 DK 2782602 T3 DK2782602 T3 DK 2782602T3 DK 12790904 T DK12790904 T DK 12790904T DK 2782602 T3 DK2782602 T3 DK 2782602T3
Authority
DK
Denmark
Prior art keywords
dims0
nucleotide
treatment
ulcerative colitis
chronic active
Prior art date
Application number
DK12790904.2T
Other languages
Danish (da)
English (en)
Inventor
Charlotte Admyre
Arezou Zargari
Stein Oliver Von
Stein Petra Von
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Application granted granted Critical
Publication of DK2782602T3 publication Critical patent/DK2782602T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK12790904.2T 2011-11-25 2012-11-23 Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis DK2782602T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190826.5A EP2596806A1 (en) 2011-11-25 2011-11-25 Method for prevention of colectomy
US201261595230P 2012-02-06 2012-02-06
PCT/EP2012/073501 WO2013076262A1 (en) 2011-11-25 2012-11-23 Method for prevention of colectomy

Publications (1)

Publication Number Publication Date
DK2782602T3 true DK2782602T3 (da) 2019-09-30

Family

ID=45094516

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12790904.2T DK2782602T3 (da) 2011-11-25 2012-11-23 Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis

Country Status (16)

Country Link
US (3) US9492516B2 (enExample)
EP (3) EP2596806A1 (enExample)
JP (2) JP6193248B2 (enExample)
CA (1) CA2892203C (enExample)
CY (1) CY1122089T1 (enExample)
DK (1) DK2782602T3 (enExample)
ES (1) ES2745677T3 (enExample)
HR (1) HRP20191723T1 (enExample)
HU (1) HUE046154T2 (enExample)
LT (1) LT2782602T (enExample)
PL (1) PL2782602T3 (enExample)
PT (1) PT2782602T (enExample)
RS (1) RS59358B1 (enExample)
SI (1) SI2782602T1 (enExample)
SM (1) SMT201900527T1 (enExample)
WO (1) WO2013076262A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881808C (en) * 2013-07-05 2021-08-17 Sony Corporation Transmission apparatus, transmission method, reception apparatus, and reception method
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201807312D0 (en) 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation
GB201818579D0 (en) * 2018-11-14 2018-12-26 Index Pharmaceuticals Ab New therapy
GB201912191D0 (en) * 2019-08-24 2019-10-09 Index Pharmaceuticals Ab New therapy
EP4147688A1 (en) * 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
JP2008526249A (ja) 2005-01-13 2008-07-24 プロジェニカ・バイオファーマ・エス・アー ｉｎｖｉｔｒｏ遺伝子タイピングのための方法および製品
EP1892293A4 (en) 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
PT2179737E (pt) 2005-07-01 2013-12-05 Index Pharmaceuticals Ab Método para modular a capacidade de resposta aos esteróides
SI2380584T1 (sl) * 2005-07-01 2014-04-30 Index Pharmaceuticals Ab Imunostimulatorni postopek
ES2560782T3 (es) * 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC

Also Published As

Publication number Publication date
EP2596806A1 (en) 2013-05-29
CA2892203C (en) 2021-11-16
JP2017061508A (ja) 2017-03-30
US20170014442A1 (en) 2017-01-19
JP6318221B2 (ja) 2018-04-25
LT2782602T (lt) 2019-10-10
WO2013076262A1 (en) 2013-05-30
US9492516B2 (en) 2016-11-15
EP2782602B1 (en) 2019-06-26
JP2015504438A (ja) 2015-02-12
PT2782602T (pt) 2019-10-14
US20180015117A1 (en) 2018-01-18
SI2782602T1 (sl) 2019-11-29
ES2745677T3 (es) 2020-03-03
RS59358B1 (sr) 2019-11-29
EP3556403A1 (en) 2019-10-23
EP2782602A1 (en) 2014-10-01
US9795627B2 (en) 2017-10-24
PL2782602T3 (pl) 2019-12-31
SMT201900527T1 (it) 2019-11-13
US20150004187A1 (en) 2015-01-01
HUE046154T2 (hu) 2020-02-28
CA2892203A1 (en) 2013-05-30
CY1122089T1 (el) 2020-11-25
JP6193248B2 (ja) 2017-09-06
HRP20191723T1 (hr) 2019-12-13

Similar Documents

Publication Publication Date Title
PL2673237T5 (pl) Zastosowanie krzemianu cyrkonu do leczenia hiperkaliemii
EP2823392A4 (en) SPECULATIVE PROCESSING AT APPLICATION LEVEL
DK2707029T3 (da) Fremgangsmåder til at behandle eller forebygge kolesterolrelaterede sygdomme
HRP20180237T1 (hr) Metode za liječenje hcv-a
LT2701773T (lt) Injekcinio švirkšto dozės kreiptuvai
IL231351A0 (en) Amino-substituted imidazopyridazines
EP2661169A4 (en) SELF-DRIVEN FUSIONING
HUE046154T2 (hu) A DIMS0-150 nukleotid alkalmazása a krónikus aktív fekélyes vastagbélgyulladás kezelésében
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
EP2688378A4 (en) Substrate unit
DK2773648T3 (da) Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion
HUE063599T2 (hu) Eljárások ödémás fibroszklerotikus pannikulopátia kezelésére vagy csökkentésére
DK2489413T5 (da) Behandlingsapparat
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
IL229081A0 (en) Isoxazolines as therapeutic agents
GB201110781D0 (en) Liquid treatment systems
IL237150A0 (en) Treatment regimens
FI20116093L (fi) Vettä käsittelevä laitos
IL228729A0 (en) Treatment regimens
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
DK2694056T3 (da) Terapeutisk behandling
HUE040153T2 (hu) Transzdermális vénás hozzáférést gátló oldatok
DK2704705T3 (da) Anvendelse af bethanechol til behandling af xerostomi
HRP20150141T1 (xx) Upotreba nifuratela u lijeäśenju infekcija uzrokovanih klostridijima
FI20115683A0 (fi) Pinnankäsittelylaite